[
    [
        {
            "time": "2020-03-22",
            "original_text": "【东吴医药】周观点20200322：国产新冠疫苗研发和国际同步，建议关注康希诺、复星医药、智飞生物",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "研发",
                    "康希诺",
                    "复星医药",
                    "智飞生物"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]